In vitro and In vivo research in cancer biology
Resume:
SHEETAL PARIDA, PhD
Email: **********@*****.***
Phone 408-***-****
ADDRESS
SUNNYVALE, CA, 94085
EDUCATION
**** ** ****, ***, ****** biology
School of Medical Science and Technology, Indian Institute of Technology,Kharagpur, India
Under the supervision of Dr.Mahitosh Mandal, Associate Professor, School of Medical Science and Technology, IIT Kharagpur, India.
Research topic: Combining EP4 prostanoid receptor inhibition with photothermal therapy for effective treatment of cervical cancer.
• My research focuses on the therapeutic significance of prostanoid inhibition in cervical cancer and its combination with gold nanoparticle mediated photothermal therapy.
• I have studied the efficacy of GW627368X, a selective EP4 prostanoid receptor antagonist in treatment of cervical cancer in vitro and in vivo and elucidated its mechanism of action. I have also conducted a preclinical safety assessment of GW627368X treatment in mice sarcoma model.
• I utilized a combination treatment modality of EP4 receptor antagonism and photothermal therapy using gold nanoprticles. I designed multifunctional, drug loaded gold nanorod cored polymeric micelles allowing targeted drug delivery and photothermal activity simultaneously and elucidated the molecular mechanism of photothermal therapy induced cell death in cancer.
2009 to 2011, M.Sc, Life Science,
National Institute of Technology, Rourkela, India
2006 to 2009, B.Sc, Biotechnology
Bangalore University, India
Relevant graduate courses: Microbiology, Biochemistry, Cell Biology, Immunology, Molecular Biology, Enzymology and Metabolism, Bioanalytical techniques, Physical Science and Instrumentation, Bioenergetics, Developmental Biology, Cancer Biology, Medical Biotechnology, Biostatistics, Advanced Biomaterials, Biomaterials for Artificial implants, Basic human anatomy physiology and pathology, Society Science and technology.
TECHNICAL SKILLS
Animal cell culture (Primary and immortalized cell lines)
Microbial Techniques (Culture and maintenance, Isolation and chacterization, Stress response studies etc.)
Microscopy (Phase contrast, Fluorescence, SEM, TEM)
In vitro and In vivo assays (Angiogenesis,Migration, Proliferation,Apoptosis,Necrosis,Necroptosis,Autophagy,Senescence, Enzymatic assays, Biochemical assays)
Nanopatricle synthesis and characterization for anticancer drug delivery and anticancer drug delivery in vitro and in vivo.
Cancer therapeutics and Anti-cancer drug screening, Cancer multidrug resistance, Preclinical evaluation of anti-cancer drugs
Photothermal therapy
Gel Electrophoresis, Western Blot, Subcellular fractionation
Immunoflorescence, Imuunocytochemistry, Immunohistochemistry
Basic molecular biology Techniques
PCR, Cloning, Transfection
Flowcytometry
Laboratory animal (Rodent) handling, cancer models (Xenograft, Sarcoma, Leukemia)
Biostatistical analyses and Computational skills
RESEARCH EXPERIENCE
PhD (2011-2016)
Topic: Combining EP4 prostanoid receptor inhibition with photothermal therapy for effective treatment of cervical cancer
Research area: Cancer Biology
M.Sc Dissertation 2010-11, Department of Life Science, NIT Rourkela, India.
Isolation and characterization of biofilm-forming bacteria and associated extracellular polymeric substances from oral cavity
Summer Internship (May to August,2010) ; Environment and Sustainability Department, Institute of Minerals and Materials Technology (CSIR) Bhubaneswar-751013, India
In vitro antimicrobial screening of leaf and stem extracts of Vitex Peduncularis Wall. Ex Schauer
MENTORING EXPERIENCE
Mentored Master’s dissertation for students pursuing Masters in Medical Science and Technology (MMST), School of Medical Science and Technology, IIT Kharagpur
Projects mentored
• Development of Carcinogen induced Rat leukemia model (2015)
• Selective Leukapheresis: A novel technique for in-vivo cytoreduction of circulating tumour cells from blood in leukaemia (2015)
• Effect of PF04418948, a novel, potent selective prostanoid EP2 receptor antagonist on the cancer of cervix (2014)
PATENT
Selective leukapheresis. System for cytoreduction of circulating cancer cells from blood and a method there of; Pankaj Chatrala, Sheetal Parida, Mahitosh Mandal. (Patent No: 868/KOL/2015) (Provisional)
PUBLICATIONS
1. Parida S, Maiti C, Y Rajesh, Dey KK, Pal I, Patra R, Dhara D, Dutta PK, Mandal M; Gold nanorod embedded reduction responsive block copolymer micelle-triggered drug delivery combined with photothermal ablation for targeted cancer therapy, BBA General Subjects doi: 10.1016/j.bbagen.2016.10.004.
2. Parida S, Pal I, Parekh A, Thakur B, Bharti R, Das S, Mandal M. GW627368X inhibits
3. proliferation and induces apoptosis in cervical cancer by interfering with EP4/EGFR interactive signaling, Cell Death and Disease 2016 Mar 24;7:e2154. doi: 10.1038/cddis.2016.61
4. Parida S, Parekh A, Dey G, Ghosh SC, Mandal M. Molecular inhibition of prostaglandin E2 with GW627368X: Therapeutic potential and preclinical safety assessment in mouse sarcoma model, Cancer Biol Ther 2015 20;16(6):922-32.
5. Parida S, Mandal M. Inflammation induced by human papillomavirus in cervical cancer and its implication in prevention, Eur J Cancer Prev 2014; 23(5): 432-48
6. Bharti R, Dey G, Banerjee I, Dey KK, Parida S, Kumar B.N, Das CK, Pal I, Mukherjee M, Misra M, Pradhan AK, Emdad L, Das SK, Fisher PB, Mandal M. Somatostain receptor targeted liposomes with Diacerein inhibit IL-6 for breast cancer therapy. Cancer letters DOI: http://dx.doi.org/10.1016/j.canlet.2016.12.021
7. Dutta S, Parida S, Maiti C, Banerjee R, Mandal M, Dhara D. Polymer Grafted Magnetic Nanoparticles for Delivery of Anticancer Drug at Lower pH and Elevated Temperature. JCIS, 2016; 467: 70-80
8. Pal I, Dey KK, Chaurasia M, Parida S, Das S, Y Rajesh, Kharbandra K, Chowdhury T, Mandal M. BI-69A11 in combination with Celecoxib enhances radiosensitization in colon cancer by modulating DNA repair activity. Tumour Biol. 2016; 37(5): 6389-402
9. Pal I, Parida S, Kumar BN, Banik P, Dey KK, Chakraborty S, Bhutia SK, Mandal M. Blockade of autophagy enhances proapoptotic potential of BI-69A11, a novel Akt inhibitor, in colon carcinoma, Eur J Pharmacol 2015; 765:217-227
10. Banerjee R, Parida S, Maiti C, Mandal M, Dhara D. pH-Degradable and Thermoresponsive Water-Soluble Core Cross-Linked Polymeric Nanoparticles as Potential Drug Delivery Vehicle for Doxorubicin, RSC Advances 2015; 5: 835**-*****
11. Kumar BN, Rajput S, Bharti R, Parida S, Mandal M. BI2536 – A PLK inhibitor augments paclitaxel efficacy in suppressing tamoxifen induced senescence and resistance in breast cancer cells, Biomedicine & Pharmacotherapy 2015; 74: 124–132
12. Dey KK, Pal I, Bharti R, Dey G, Kumar BN, Rajput S, Parekh A, Parida S,Halder P,Kulavi I, Mandal M. Identification of RAB2A and PRDX1 as the potential biomarkers for oral squamous cell carcinoma using mass spectrometry-based comparative proteomic approach. Tumour Biol. 2015; 36(12): 9829-37
13. Rajput S, Kumar B.N, Banik P, Parida S, Mandal M. Thymoquinone restores radiation induced TGF-β expression and abrogates EMT in chemoradiotherapy of breast cancer cells, J cell physiol 2015; 230(3): 620-9
14. Jain K, Parida S, Mangwani N, Dash H.R, Das S. Isolation and characterization of biofilm-forming bacteria and associated extracellular polymeric substances from oral cavity, Ann microbial 2013; 63(2013): 1553-62
15. Dey G, Bharti R, Banik P, Pal I, Parekh A, Parida S, Rajesh Y, Sen R, Mandal M . Microbial green lipopeptide 'Iturin A' inhibits angiogenesis and tumor invasion via modulating Akt/IKKα/NF-κB signaling axis, CDD-15-0889 (Under Review)
16. Parekh A, Das S, Parida S, Das CK, Dutta D, Mallick SK, Kumar BN, Bharti R, Dey G, Rajput S, Banerjee K, Pal I, Dey KK, Banik P, Rajesh Y, Jena BC, Pradhan A, Das SK, Das AK, Dhara S, Fisher PB, Mills GB, Mandal M. Breast cancer multi-nucleated cells induce chemoresistance through production of vegf and mif. CANCER-CELL-D-16-00434(Under consideration)
Book chapter:
1. Parida and Mandal (2014). Mechanism controlling blood vessel growth and development and identification of therapeutics against pathological angiogenesis. Antiangiogenesis drug discovery and development; 2(60): 2-63. Bentham Science.
CONFERENCE ABSTRACTS
1. Managing cervical cancer using multifunctional gold nanorods. Sheetal Parida, Mahitosh Mandal. Cancer Res, 2015 75;3685 doi: 10.1158/1538-7445.AM2015-3685
2. BI-69A11 promotes autophagy as an early event followed by the induction of apoptosis. Ipsita Pal, Sheetal Parida, Kaushik Kumar Dey, Mahitosh Mandal. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23, Volume: Mol Cancer Ther 2013;12(11 Suppl):C16.
3. Combinatorial Effect of ZD6474 and Thymoquinone Inhibits Src Mediated ERK-1/2/STAT3 Signalling and Renders Antimetastasis in Breast Cancer.Shashi Rajput, B.N. Prashanth Kumar, Kaushik k. Dey, Ipsita Pal, Kacoli Sen, Goutam Dey, Rashmi Bharti, Sheetal Parida, Aditya Parekh, Mahitosh Mandal. 24 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. European Journal of Cancer. 11/2012; 48(November, 2012):61. DOI: 10.1016/S0959-8049(12)71999-8
4. Enhanced susceptibility to apoptotic induction by Mcl-1 inhibition through synergistic mechanism of celecoxib and betulinic acid in breast cancer. B.N.Prashanth Kumar, Shashi Rajput, Kaushik k. Dey, Ipsita Pal, Kacoli Sen, Goutam Dey, Rashmi Bharti, Sheetal Parida, Aditya Parekh, Mahitosh Mandal. 24 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. European Journal of Cancer. 11/2012; 48(November, 2012):24. DOI: 10.1016/S0959-8049(12)71870-1
5. Effect of GW627368X, a novel, potent, selective prostanoid EP4 receptor antagonist on cancer of cervix. Sheetal Parida, Ipsita Pal, Mahitosh Mandal. 33rd Annual Convention of IACR, 2014
6. Contrasting characteristics of drug resistance in breast cancer. Aditya Parekh, B.N. Prashanth Kumar, Shashi Rajput, Sheetal Parida, Goutam Dey, Mahitosh Mandal. 33rd Annual Convention of IACR, 2014
REFERENCES
Contact this candidate